Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBITDA: 2017-2024

Historic EBITDA for Puma Biotechnology (PBYI) over the last 8 years, with Dec 2024 value amounting to $31.0 million.

  • Puma Biotechnology's EBITDA fell 56.64% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of $31.0 million for FY2024, which is 5.13% down from last year.
  • According to the latest figures from FY2024, Puma Biotechnology's EBITDA is $31.0 million, which was down 5.13% from $32.6 million recorded in FY2023.
  • Puma Biotechnology's EBITDA's 5-year high stood at $32.6 million during FY2023, with a 5-year trough of -$30.4 million in FY2020.
  • Over the past 3 years, Puma Biotechnology's median EBITDA value was $31.0 million (recorded in 2024), while the average stood at $29.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first spiked by 492.39% in 2022, then fell by 5.13% in 2024.
  • Yearly analysis of 5 years shows Puma Biotechnology's EBITDA stood at -$30.4 million in 2020, then spiked by 80.12% to -$6.0 million in 2021, then surged by 492.39% to $23.7 million in 2022, then spiked by 37.61% to $32.6 million in 2023, then dropped by 5.13% to $31.0 million in 2024.